Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.
This prospective study aimed to investigate the influence of pretransplant serum ferritin levels on the outcomes of allogeneic hematopoietic SCT (HSCT). In total, 190 patients with acute leukemia or myelodysplastic syndrome were consecutively enrolled. The patients were divided into two groups: low-ferritin group (<1000 ng/mL) and high-ferritin group (⩾1000 ng/mL). The primary end point was the cumulative incidence of infection within 100 days after HSCT, which was similar between the two groups: bloodstream infection, 35 vs 38%, P=0.65; bacterial infection, 44 vs 41%, P=0.68; and fungal infection, 6 vs 8%, P=0.71. The 1-year adjusted probability of OS of the high-ferritin group was significantly lower than that of the low-ferritin group (76 vs 63%, P=0.017). Using receiver operating characteristic curve, the threshold of pretransplant serum ferritin levels for bloodstream infection was 1400 ng/mL; the threshold for OS, EFS and non-relapse mortality was 1349 ng/mL. In conclusion, pretransplant serum ferritin levels of ⩾1000 ng/mL did not influence the incidence of infection but adversely affected OS after HSCT. A higher threshold of pretransplant serum ferritin levels may predict HSCT outcomes.
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
M
M
Tanaka
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
H
H
Kanamori
Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
K
K
Matsumoto
1] Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan [2] Department of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
T
T
Tachibana
1] Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan [2] Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
A
A
Numata
Division of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
K
K
Ohashi
Division of Hematology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
T
T
Kobayashi
Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Japan.
C
C
Nakaseko
Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Y
Y
Kanda
Department of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
E
E
Yamazaki
Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
S
S
Fujisawa
Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
J
J
Ooi
Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
T
T
Sakura
Department of Hematology, Narita Red Cross Hospital, Narita, Japan.
N
N
Aotsuka
Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
M
M
Onoda
Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
S
S
Machida
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
J
J
Kato
Division of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
K
K
Usuki
Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
R
R
Watanabe
Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan.
J
J
Taguchi
Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
S
S
Yano
Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
T
T
Saito
Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
S
S
Takahashi
Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
H
H
Sakamaki
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
S
S
Okamoto
D000328:Adult; D000368:Aged; D064591:Allografts; D001424:Bacterial Infections / Q000097:blood / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005293:Ferritins / Q000097:blood*; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000097:blood / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000097:blood / Q000401:mortality; D057234:Preoperative Period; D011446:Prospective Studies; D015996:Survival Rate
D005293:Ferritins